Opus Genetics, Inc. IRD
Opus Genetics, Inc. (the "Company," "Opus," "we," "us," or "our") is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent
blindness in patients with inherited retinal diseases ("IRDs"), and other types of therapies for additional ophthalmic disorders.
In April 2018, Ocuphire Pharma, Inc. merged with Ocularis Pharma, LLC, the original innovator of phentolamine mesylate ophthalmic solution.
In January 2020, Ocuphire Pharma, Inc. obtained from Apexian Pharmaceuticals, Inc. certain rights to its Ref-1 inhibitor program, including APX3330.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589.0K | $0 | $3.0M | — | — | — |
| R&D | — | — | — | — | — | — | $5.5M | $13.1M | $10.7M | $10.1M |
| SG&A | $22.0M | $18.2M | $12.0M | $7.3M | $8.1M | $2.8M | $1.8M | $7.4M | $6.6M | $6.3M |
| Total operating expenses | $52.8M | $73.1M | $29.6M | $21.6M | $23.3M | $20.0M | $4.2M | $20.5M | $17.4M | $16.4M |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M | -$22.7M | -$20.0M | -$4.2M | -$20.5M | -$17.4M | -$16.4M |
| Interest expense | $129.0K | $0 | $0 | $9.0K | $2.0K | $6.8M | $1.4M | — | — | — |
| Pre-tax income | -$49.6M | -$57.5M | -$10.0M | $18.2M | -$56.7M | -$24.6M | -$6.2M | — | — | — |
| Income tax | $0 | $0 | $12.0K | $315.0K | $0 | $0 | $0 | — | — | — |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M | -$56.7M | -$24.6M | -$6.2M | -$14.4M | -$25.3M | -$9.3M |
| EPS, basic | -0.80 | -2.15 | -0.46 | 0.90 | -3.82 | -5.28 | — | — | — | — |
| EPS, diluted | -0.80 | -2.15 | -0.46 | 0.87 | -3.82 | -5.28 | -2.17 | -5.25 | -0.92 | -0.43 |
| Shares, diluted (wtd. avg.) | $62.2M | $26.7M | $21.6M | $20.6M | $14.9M | $4.7M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.1M | $30.3M | $50.5M | $42.6M | $24.5M | $16.4M | $1.5M | $451.0K | $8.9M | $11.6M |
| Short-term investments | $0 | $2.0K | $15.0K | $49.0K | $219.0K | $0 | — | — | — | — |
| Receivables | $2.0M | $3.6M | $926.0K | $1.3M | $0 | — | — | — | — | — |
| Total current assets | $50.0M | $36.6M | $53.9M | $49.0M | $26.1M | $17.7M | $1.8M | $15.9M | $28.1M | $20.9M |
| Property, plant and equipment | $199.0K | $252.0K | $0 | $6.0K | $10.0K | $14.0K | $22.0K | $112.5K | $121.5K | $88.7K |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M | $17.7M | $1.8M | $16.0M | $28.3M | $21.0M |
| Accounts payable | $3.3M | $3.1M | $2.2M | $1.1M | $1.6M | $1.2M | $342.0K | $3.2M | $3.2M | $1.9M |
| Short-term debt | — | — | — | $0 | $600.0K | $0 | — | — | — | — |
| Total current liabilities | $7.8M | $11.3M | $4.0M | $2.8M | $3.9M | $3.2M | $9.3M | $3.2M | — | — |
| Long-term debt | $1.1M | $0 | — | — | — | — | — | — | — | — |
| Total liabilities | $34.9M | $11.3M | $4.0M | $2.8M | $3.9M | $31.1M | $9.3M | $5.5M | $11.5M | $4.0M |
| Retained earnings | -$188.6M | -$139.0M | -$81.5M | -$71.5M | -$89.4M | -$32.7M | -$8.1M | -$154.7M | -$140.3M | -$115.0M |
| Total equity | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M | -$13.5M | -$7.6M | -$1.7M | $16.8M | $17.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M | -$19.4M | -$6.8M | -$3.6M | -$18.8M | -$15.4M | -$13.2M |
| Depreciation and amortisation | $53.0K | $10.0K | $6.0K | $4.0K | $4.0K | $8.0K | $3.0K | — | — | — |
| Stock-based compensation | $3.4M | $3.4M | $3.5M | $1.8M | $1.9M | $1.5M | $308.0K | $1.2M | $1.0M | $1.4M |
| Capital expenditure | — | — | — | — | — | $0 | $25.0K | — | — | — |
| Investing cash flow | $0 | $1.2M | $0 | $0 | -$100.0K | $539.0K | -$25.0K | $11.9M | -$9.4M | $4.5M |
| Financing cash flow | $50.0M | $4.2M | $9.0M | $3.8M | $27.6M | $21.1M | $4.7M | $6.8M | $22.1M | $10.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-009247.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |